Publications of Yvonne Genzel

Talk (130)

161.
Talk
Pelz, L.; Rüdiger, D.; Hein, M. D.; Böhme, J.; Bälkner, M.; Kershaw, O.; Marichal-Gallardo, P.; Gruber, A.; Genzel, Y.; Bruder, D. et al.; Kupke, S. Y.; Reichl, U.: Genetic engineering of Influenza A virus defective interfering particles towards improved antiviral efficacy and potential use as a live vaccine. Vaccine Technology IX, Los Cabos (Mexico) (2024)
162.
Talk
Zinnecker, T. M.; Thiele, K.; Schmidberger, T.; Reichl, U.; Genzel, Y.: Influenza A Virus Production following Quality by Design Principles. Vaccine Technology IX, Los Cabos (Mexico) (2024)
163.
Talk
Dogra, T.; Pelz, L.; Boehme, J. D.; Baelkner, M.; Kershaw, O.; Marichal-Gallardo, P.; Gruber, A. D.; Genzel, Y.; Bruder, D.; Kupke, S. Y. et al.; Reichl, U.: Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 17th Vaccine Congress, Glasgow (Scotland) (2023)
164.
Talk
Genzel, Y.: ESACT Course on Cell Culture-based Viral Vaccines (8th Edition): Exercise on vaccine design. ESACT Course 2023, Llafranc (Spain) (2023)
165.
Talk
Genzel, Y.: ESACT Course on Cell Culture-based Viral Vaccines (8th Edition): Overview on COVID-19 candidate vaccines. Introduction Exercise. ESACT Course 2023, Llafranc (Spain) (2023)
166.
Talk
Genzel, Y.: ESACT Course on Cell Culture-based Viral Vaccines (8th Edition):Upstream Process Intensification. ESACT Course 2023, Llafranc (Spain) (2023)
167.
Talk
Genzel, Y.: ESACT Course on Cell Culture-based Viral Vaccines (8th Edition):Upstream Process Development - From Master Seed to Production. ESACT Course 2023, Llafranc (Spain) (2023)
168.
Talk
Genzel, Y.; Zinnecker, T. M.; Göbel, S.; Reichl, U.: Intensified cell-based virus production: A process development challenge for multiple cell-virus combinations. 16th PEACe Conference, Sitges (Spain) (2023)
169.
Talk
Genzel, Y.; Zinnecker, T. M.; Göbel, S.; Reichl, U.: Next-Generation Virus Production: From Clone, to AMBR, to Perfusion and Very High Virus Yield. International Society for Vaccines (ISV) Annual Congress, Lausanne (Switzerland) (2023)
170.
Talk
Genzel, Y.; Zinnecker, T. M.; Göbel, S.; Reichl, U.: Increase in supply through use of new technologies for high yield vaccines. Flanders Vaccine, Brussels (Belgium) (2023)
171.
Talk
Göbel, S.; Dallmeier, K.; Jordan, I.; de Jong, J.; Reichl, U.; Genzel, Y.: Intensified production for a yellow fever - ZIKA virus vaccine candicate. Democratization of biotherapies: new manufacturing modalities and intensification's, Oxford, UK (2023)
172.
Talk
Göbel, S.; Jaén, K. E.; Pelz, L.; Reiter , M.; Altomonte, J.; Reichl, U.; Genzel, Y.: Intensifiying OSB processes for high titer virus production. 5th large scale meeting: Orbital shaken bioreactors, Girona (Spain) (2023)
173.
Talk
Küchler, J.; Opitz, P.; Rüdiger, D.; Kupke, S. Y.; Genzel, Y.; Benndorf, D.; Reichl, U.: Absolute quantification of influenza A virus proteins during single-round replication in different host cells. 6th Workshop on Virus Dynamics, Nagoya (Japan) (2023)
174.
Talk
Pelz, L.; Dogra, T.; Boehme, J.D.; Hein, M. D.; Marichal-Gallardo, P.; Genzel, Y.; Bruder, D.; Kupke, S. Y.; Reichl, U.: Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)
175.
Talk
Pelz, L.; Genzel, Y.; Kupke, S. Y.; Reichl, U.: In-depth characterization and cell culture-based production of influenza A virus defective interfering particles. ACTIP fellowship session, Dublin (Ireland) (2023)
176.
Talk
Pelz, L.; Rüdiger, D.; Dogra, T.; Alnaji, F. D.; Genzel, Y.; Brooke, C. B.; Kupke, S. Y.; Reichl, U.: Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral Therapy. Vir-AI-DIP Workshop, Hamburg (Germany) (2023)
177.
Talk
Zinnecker, T. M.; Badri, N.; Araujo, D.; Hinkelmann, A.; Thiele, K.; Reichl, U.; Genzel, Y.: Novel approach towards vaccine manufacturing: from single-cell cloning to high-yielding influenza virus production. 4th Global Bioprocessing, Bioanalytics and ATMP Manufacturing Congress, Dublin (Ireland) (2023)
178.
Talk
Zinnecker, T. M.; Badri, N.; Araujo, D.; Hinkelmann, A.; Thiele, K.; Reichl, U.; Genzel, Y.: A quest for the best influenza producing clonal MDCK cell line: intensifying by design of experiments, ambr15 and bench-top bioreactor cultivations. World Biopharm Forum 2023 - Democratisation of biotherapies: new manufacturing modalities and intensifications, Oxford (United Kingdom) (2023)
179.
Talk
Genzel, Y.: ESACT Course on Cell Culture-based Viral Vaccines (7th Edition):Upstream Process Development - From Master Seed to Production. ESACT Course 2022, Llafranc (Spain) (2022)
180.
Talk
Genzel, Y.: ESACT Course on Cell Culture-based Viral Vaccines (7th Edition):Upstream Process Intensification. ESACT Course 2022, Llafranc (Spain) (2022)
Go to Editor View